1 Study Coverage 1.1 Influenzavirus B Infection Drug Product Introduction 1.2 Market Segments 1.3 Key Influenzavirus B Infection Drug Manufacturers Covered: Ranking by Revenue 1.4 Market by Type 1.4.1 Global Influenzavirus B Infection Drug Market Size Growth Rate by Type 1.4.2 APP-309 1.4.3 CF-403 1.4.4 GC-3106A 1.4.5 KIN-1400 1.4.6 Others 1.5 Market by Application 1.5.1 Global Influenzavirus B Infection Drug Market Size Growth Rate by Application 1.5.2 Clinic 1.5.3 Hospital 1.5.4 Others 1.6 Study Objectives 1.7 Years Considered 2 Executive Summary 2.1 Global Influenzavirus B Infection Drug Market Size, Estimates and Forecasts 2.1.1 Global Influenzavirus B Infection Drug Revenue 2015-2026 2.1.2 Global Influenzavirus B Infection Drug Sales 2015-2026 2.2 Global Influenzavirus B Infection Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026 2.3 Influenzavirus B Infection Drug Historical Market Size by Region (2015-2020) 2.3.1 Global Influenzavirus B Infection Drug Retrospective Market Scenario in Sales by Region: 2015-2020 2.3.2 Global Influenzavirus B Infection Drug Retrospective Market Scenario in Revenue by Region: 2015-2020 2.4 Influenzavirus B Infection Drug Market Estimates and Projections by Region (2021-2026) 2.4.1 Global Influenzavirus B Infection Drug Sales Forecast by Region (2021-2026) 2.4.2 Global Influenzavirus B Infection Drug Revenue Forecast by Region (2021-2026) 3 Global Influenzavirus B Infection Drug Competitor Landscape by Players 3.1 Global Top Influenzavirus B Infection Drug Sales by Manufacturers 3.1.1 Global Influenzavirus B Infection Drug Sales by Manufacturers (2015-2020) 3.1.2 Global Influenzavirus B Infection Drug Sales Market Share by Manufacturers (2015-2020) 3.2 Global Influenzavirus B Infection Drug Manufacturers by Revenue 3.2.1 Global Influenzavirus B Infection Drug Revenue by Manufacturers (2015-2020) 3.2.2 Global Influenzavirus B Infection Drug Revenue Share by Manufacturers (2015-2020) 3.2.3 Global Influenzavirus B Infection Drug Market Concentration Ratio (CR5 and HHI) (2015-2020) 3.2.4 Global Top 10 and Top 5 Companies by Influenzavirus B Infection Drug Revenue in 2019 3.2.5 Global Influenzavirus B Infection Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.3 Global Influenzavirus B Infection Drug Price by Manufacturers 3.4 Global Influenzavirus B Infection Drug Manufacturing Base Distribution, Product Types 3.4.1 Influenzavirus B Infection Drug Manufacturers Manufacturing Base Distribution, Headquarters 3.4.2 Manufacturers Influenzavirus B Infection Drug Product Type 3.4.3 Date of International Manufacturers Enter into Influenzavirus B Infection Drug Market 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans 4 Market Size by Type (2015-2026) 4.1 Global Influenzavirus B Infection Drug Market Size by Type (2015-2020) 4.1.1 Global Influenzavirus B Infection Drug Sales by Type (2015-2020) 4.1.2 Global Influenzavirus B Infection Drug Revenue by Type (2015-2020) 4.1.3 Influenzavirus B Infection Drug Average Selling Price (ASP) by Type (2015-2026) 4.2 Global Influenzavirus B Infection Drug Market Size Forecast by Type (2021-2026) 4.2.1 Global Influenzavirus B Infection Drug Sales Forecast by Type (2021-2026) 4.2.2 Global Influenzavirus B Infection Drug Revenue Forecast by Type (2021-2026) 4.2.3 Influenzavirus B Infection Drug Average Selling Price (ASP) Forecast by Type (2021-2026) 4.3 Global Influenzavirus B Infection Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Market Size by Application (2015-2026) 5.1 Global Influenzavirus B Infection Drug Market Size by Application (2015-2020) 5.1.1 Global Influenzavirus B Infection Drug Sales by Application (2015-2020) 5.1.2 Global Influenzavirus B Infection Drug Revenue by Application (2015-2020) 5.1.3 Influenzavirus B Infection Drug Price by Application (2015-2020) 5.2 Influenzavirus B Infection Drug Market Size Forecast by Application (2021-2026) 5.2.1 Global Influenzavirus B Infection Drug Sales Forecast by Application (2021-2026) 5.2.2 Global Influenzavirus B Infection Drug Revenue Forecast by Application (2021-2026) 5.2.3 Global Influenzavirus B Infection Drug Price Forecast by Application (2021-2026) 6 Japan by Players, Type and Application 6.1 Japan Influenzavirus B Infection Drug Market Size YoY Growth 2015-2026 6.1.1 Japan Influenzavirus B Infection Drug Sales YoY Growth 2015-2026 6.1.2 Japan Influenzavirus B Infection Drug Revenue YoY Growth 2015-2026 6.1.3 Japan Influenzavirus B Infection Drug Market Share in Global Market 2015-2026 6.2 Japan Influenzavirus B Infection Drug Market Size by Players (International and Local Players) 6.2.1 Japan Top Influenzavirus B Infection Drug Players by Sales (2015-2020) 6.2.2 Japan Top Influenzavirus B Infection Drug Players by Revenue (2015-2020) 6.3 Japan Influenzavirus B Infection Drug Historic Market Review by Type (2015-2020) 6.3.1 Japan Influenzavirus B Infection Drug Sales Market Share by Type (2015-2020) 6.3.2 Japan Influenzavirus B Infection Drug Revenue Market Share by Type (2015-2020) 6.3.3 Japan Influenzavirus B Infection Drug Price by Type (2015-2020) 6.4 Japan Influenzavirus B Infection Drug Market Estimates and Forecasts by Type (2021-2026) 6.4.1 Japan Influenzavirus B Infection Drug Sales Forecast by Type (2021-2026) 6.4.2 Japan Influenzavirus B Infection Drug Revenue Forecast by Type (2021-2026) 6.4.3 Japan Influenzavirus B Infection Drug Price Forecast by Type (2021-2026) 6.5 Japan Influenzavirus B Infection Drug Historic Market Review by Application (2015-2020) 6.5.1 Japan Influenzavirus B Infection Drug Sales Market Share by Application (2015-2020) 6.5.2 Japan Influenzavirus B Infection Drug Revenue Market Share by Application (2015-2020) 6.5.3 Japan Influenzavirus B Infection Drug Price by Application (2015-2020) 6.6 Japan Influenzavirus B Infection Drug Market Estimates and Forecasts by Application (2021-2026) 6.6.1 Japan Influenzavirus B Infection Drug Sales Forecast by Application (2021-2026) 6.6.2 Japan Influenzavirus B Infection Drug Revenue Forecast by Application (2021-2026) 6.6.3 Japan Influenzavirus B Infection Drug Price Forecast by Application (2021-2026) 7 North America 7.1 North America Influenzavirus B Infection Drug Market Size YoY Growth 2015-2026 7.2 North America Influenzavirus B Infection Drug Market Facts & Figures by Country 7.2.1 North America Influenzavirus B Infection Drug Sales by Country (2015-2020) 7.2.2 North America Influenzavirus B Infection Drug Revenue by Country (2015-2020) 7.2.3 U.S. 7.2.4 Canada 8 Europe 8.1 Europe Influenzavirus B Infection Drug Market Size YoY Growth 2015-2026 8.2 Europe Influenzavirus B Infection Drug Market Facts & Figures by Country 8.2.1 Europe Influenzavirus B Infection Drug Sales by Country 8.2.2 Europe Influenzavirus B Infection Drug Revenue by Country 8.2.3 Germany 8.2.4 France 8.2.5 U.K. 8.2.6 Italy 8.2.7 Russia 9 Asia Pacific 9.1 Asia Pacific Influenzavirus B Infection Drug Market Size YoY Growth 2015-2026 9.2 Asia Pacific Influenzavirus B Infection Drug Market Facts & Figures by Country 9.2.1 Asia Pacific Influenzavirus B Infection Drug Sales by Region (2015-2020) 9.2.2 Asia Pacific Influenzavirus B Infection Drug Revenue by Region 9.2.3 China 9.2.4 Japan 9.2.5 South Korea 9.2.6 India 9.2.7 Australia 9.2.8 Taiwan 9.2.9 Indonesia 9.2.10 Thailand 9.2.11 Malaysia 9.2.12 Philippines 9.2.13 Vietnam 10 Latin America 10.1 Latin America Influenzavirus B Infection Drug Market Size YoY Growth 2015-2026 10.2 Latin America Influenzavirus B Infection Drug Market Facts & Figures by Country 10.2.1 Latin America Influenzavirus B Infection Drug Sales by Country 10.2.2 Latin America Influenzavirus B Infection Drug Revenue by Country 10.2.3 Mexico 10.2.4 Brazil 10.2.5 Argentina 11 Middle East and Africa 11.1 Middle East and Africa Influenzavirus B Infection Drug Market Size YoY Growth 2015-2026 11.2 Middle East and Africa Influenzavirus B Infection Drug Market Facts & Figures by Country 11.2.1 Middle East and Africa Influenzavirus B Infection Drug Sales by Country 11.2.2 Middle East and Africa Influenzavirus B Infection Drug Revenue by Country 11.2.3 Turkey 11.2.4 Saudi Arabia 11.2.5 U.A.E 12 Company Profiles 12.1 AbbVie Inc 12.1.1 AbbVie Inc Corporation Information 12.1.2 AbbVie Inc Description and Business Overview 12.1.3 AbbVie Inc Sales, Revenue and Gross Margin (2015-2020) 12.1.4 AbbVie Inc Influenzavirus B Infection Drug Products Offered 12.1.5 AbbVie Inc Recent Development 12.2 Adimmune Corp 12.2.1 Adimmune Corp Corporation Information 12.2.2 Adimmune Corp Description and Business Overview 12.2.3 Adimmune Corp Sales, Revenue and Gross Margin (2015-2020) 12.2.4 Adimmune Corp Influenzavirus B Infection Drug Products Offered 12.2.5 Adimmune Corp Recent Development 12.3 Altravax Inc 12.3.1 Altravax Inc Corporation Information 12.3.2 Altravax Inc Description and Business Overview 12.3.3 Altravax Inc Sales, Revenue and Gross Margin (2015-2020) 12.3.4 Altravax Inc Influenzavirus B Infection Drug Products Offered 12.3.5 Altravax Inc Recent Development 12.4 Amarillo Biosciences Inc 12.4.1 Amarillo Biosciences Inc Corporation Information 12.4.2 Amarillo Biosciences Inc Description and Business Overview 12.4.3 Amarillo Biosciences Inc Sales, Revenue and Gross Margin (2015-2020) 12.4.4 Amarillo Biosciences Inc Influenzavirus B Infection Drug Products Offered 12.4.5 Amarillo Biosciences Inc Recent Development 12.5 Aphios Corp 12.5.1 Aphios Corp Corporation Information 12.5.2 Aphios Corp Description and Business Overview 12.5.3 Aphios Corp Sales, Revenue and Gross Margin (2015-2020) 12.5.4 Aphios Corp Influenzavirus B Infection Drug Products Offered 12.5.5 Aphios Corp Recent Development 12.6 BioCryst Pharmaceuticals Inc 12.6.1 BioCryst Pharmaceuticals Inc Corporation Information 12.6.2 BioCryst Pharmaceuticals Inc Description and Business Overview 12.6.3 BioCryst Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020) 12.6.4 BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Products Offered 12.6.5 BioCryst Pharmaceuticals Inc Recent Development 12.7 Cadila Healthcare Ltd 12.7.1 Cadila Healthcare Ltd Corporation Information 12.7.2 Cadila Healthcare Ltd Description and Business Overview 12.7.3 Cadila Healthcare Ltd Sales, Revenue and Gross Margin (2015-2020) 12.7.4 Cadila Healthcare Ltd Influenzavirus B Infection Drug Products Offered 12.7.5 Cadila Healthcare Ltd Recent Development 12.8 ContraFect Corp 12.8.1 ContraFect Corp Corporation Information 12.8.2 ContraFect Corp Description and Business Overview 12.8.3 ContraFect Corp Sales, Revenue and Gross Margin (2015-2020) 12.8.4 ContraFect Corp Influenzavirus B Infection Drug Products Offered 12.8.5 ContraFect Corp Recent Development 12.9 Daiichi Sankyo Company Ltd 12.9.1 Daiichi Sankyo Company Ltd Corporation Information 12.9.2 Daiichi Sankyo Company Ltd Description and Business Overview 12.9.3 Daiichi Sankyo Company Ltd Sales, Revenue and Gross Margin (2015-2020) 12.9.4 Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Products Offered 12.9.5 Daiichi Sankyo Company Ltd Recent Development 12.10 Fujifilm Holdings Corporation 12.10.1 Fujifilm Holdings Corporation Corporation Information 12.10.2 Fujifilm Holdings Corporation Description and Business Overview 12.10.3 Fujifilm Holdings Corporation Sales, Revenue and Gross Margin (2015-2020) 12.10.4 Fujifilm Holdings Corporation Influenzavirus B Infection Drug Products Offered 12.10.5 Fujifilm Holdings Corporation Recent Development 12.11 AbbVie Inc 12.11.1 AbbVie Inc Corporation Information 12.11.2 AbbVie Inc Description and Business Overview 12.11.3 AbbVie Inc Sales, Revenue and Gross Margin (2015-2020) 12.11.4 AbbVie Inc Influenzavirus B Infection Drug Products Offered 12.11.5 AbbVie Inc Recent Development 12.12 Green Cross Corp 12.12.1 Green Cross Corp Corporation Information 12.12.2 Green Cross Corp Description and Business Overview 12.12.3 Green Cross Corp Sales, Revenue and Gross Margin (2015-2020) 12.12.4 Green Cross Corp Products Offered 12.12.5 Green Cross Corp Recent Development 12.13 Inovio Pharmaceuticals Inc 12.13.1 Inovio Pharmaceuticals Inc Corporation Information 12.13.2 Inovio Pharmaceuticals Inc Description and Business Overview 12.13.3 Inovio Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020) 12.13.4 Inovio Pharmaceuticals Inc Products Offered 12.13.5 Inovio Pharmaceuticals Inc Recent Development 12.14 Kineta Inc 12.14.1 Kineta Inc Corporation Information 12.14.2 Kineta Inc Description and Business Overview 12.14.3 Kineta Inc Sales, Revenue and Gross Margin (2015-2020) 12.14.4 Kineta Inc Products Offered 12.14.5 Kineta Inc Recent Development 12.15 Medicago Inc 12.15.1 Medicago Inc Corporation Information 12.15.2 Medicago Inc Description and Business Overview 12.15.3 Medicago Inc Sales, Revenue and Gross Margin (2015-2020) 12.15.4 Medicago Inc Products Offered 12.15.5 Medicago Inc Recent Development 12.16 MedImmune LLC 12.16.1 MedImmune LLC Corporation Information 12.16.2 MedImmune LLC Description and Business Overview 12.16.3 MedImmune LLC Sales, Revenue and Gross Margin (2015-2020) 12.16.4 MedImmune LLC Products Offered 12.16.5 MedImmune LLC Recent Development 12.17 Mucosis BV 12.17.1 Mucosis BV Corporation Information 12.17.2 Mucosis BV Description and Business Overview 12.17.3 Mucosis BV Sales, Revenue and Gross Margin (2015-2020) 12.17.4 Mucosis BV Products Offered 12.17.5 Mucosis BV Recent Development 12.18 Novavax Inc 12.18.1 Novavax Inc Corporation Information 12.18.2 Novavax Inc Description and Business Overview 12.18.3 Novavax Inc Sales, Revenue and Gross Margin (2015-2020) 12.18.4 Novavax Inc Products Offered 12.18.5 Novavax Inc Recent Development 12.19 Park Active Molecules 12.19.1 Park Active Molecules Corporation Information 12.19.2 Park Active Molecules Description and Business Overview 12.19.3 Park Active Molecules Sales, Revenue and Gross Margin (2015-2020) 12.19.4 Park Active Molecules Products Offered 12.19.5 Park Active Molecules Recent Development 12.20 Romark Laboratories LC 12.20.1 Romark Laboratories LC Corporation Information 12.20.2 Romark Laboratories LC Description and Business Overview 12.20.3 Romark Laboratories LC Sales, Revenue and Gross Margin (2015-2020) 12.20.4 Romark Laboratories LC Products Offered 12.20.5 Romark Laboratories LC Recent Development 12.21 Sanofi 12.21.1 Sanofi Corporation Information 12.21.2 Sanofi Description and Business Overview 12.21.3 Sanofi Sales, Revenue and Gross Margin (2015-2020) 12.21.4 Sanofi Products Offered 12.21.5 Sanofi Recent Development 12.22 Sanofi Pasteur SA 12.22.1 Sanofi Pasteur SA Corporation Information 12.22.2 Sanofi Pasteur SA Description and Business Overview 12.22.3 Sanofi Pasteur SA Sales, Revenue and Gross Margin (2015-2020) 12.22.4 Sanofi Pasteur SA Products Offered 12.22.5 Sanofi Pasteur SA Recent Development 12.23 Shionogi & Co Ltd 12.23.1 Shionogi & Co Ltd Corporation Information 12.23.2 Shionogi & Co Ltd Description and Business Overview 12.23.3 Shionogi & Co Ltd Sales, Revenue and Gross Margin (2015-2020) 12.23.4 Shionogi & Co Ltd Products Offered 12.23.5 Shionogi & Co Ltd Recent Development 12.24 SK Chemicals Co Ltd 12.24.1 SK Chemicals Co Ltd Corporation Information 12.24.2 SK Chemicals Co Ltd Description and Business Overview 12.24.3 SK Chemicals Co Ltd Sales, Revenue and Gross Margin (2015-2020) 12.24.4 SK Chemicals Co Ltd Products Offered 12.24.5 SK Chemicals Co Ltd Recent Development 12.25 TSRL Inc 12.25.1 TSRL Inc Corporation Information 12.25.2 TSRL Inc Description and Business Overview 12.25.3 TSRL Inc Sales, Revenue and Gross Margin (2015-2020) 12.25.4 TSRL Inc Products Offered 12.25.5 TSRL Inc Recent Development 12.26 Vaxart Inc 12.26.1 Vaxart Inc Corporation Information 12.26.2 Vaxart Inc Description and Business Overview 12.26.3 Vaxart Inc Sales, Revenue and Gross Margin (2015-2020) 12.26.4 Vaxart Inc Products Offered 12.26.5 Vaxart Inc Recent Development 12.27 Vectura Group Plc 12.27.1 Vectura Group Plc Corporation Information 12.27.2 Vectura Group Plc Description and Business Overview 12.27.3 Vectura Group Plc Sales, Revenue and Gross Margin (2015-2020) 12.27.4 Vectura Group Plc Products Offered 12.27.5 Vectura Group Plc Recent Development 13 Market Opportunities, Challenges, Risks and Influences Factors Analysis 13.1 Market Opportunities and Drivers 13.2 Market Challenges 13.3 Market Risks/Restraints 13.4 Porter’s Five Forces Analysis 13.5 Primary Interviews with Key Influenzavirus B Infection Drug Players (Opinion Leaders) 14 Value Chain and Sales Channels Analysis 14.1 Value Chain Analysis 14.2 Influenzavirus B Infection Drug Customers 14.3 Sales Channels Analysis 14.3.1 Sales Channels 14.3.2 Distributors 15 Research Findings and Conclusion 16 Appendix 16.1 Research Methodology 16.1.1 Methodology/Research Approach 16.1.2 Data Source 16.2 Author Details 16.3 Disclaimer

List of Tables Table 1. Influenzavirus B Infection Drug Market Segments Table 2. Ranking of Global Top Influenzavirus B Infection Drug Manufacturers by Revenue (US$ Million) in 2019 Table 3. Global Influenzavirus B Infection Drug Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million) Table 4. Major Manufacturers of APP-309 Table 5. Major Manufacturers of CF-403 Table 6. Major Manufacturers of GC-3106A Table 7. Major Manufacturers of KIN-1400 Table 8. Major Manufacturers of Others Table 9. Global Influenzavirus B Infection Drug Market Size Growth Rate by Application 2020-2026 (K Pcs) Table 10. Global Influenzavirus B Infection Drug Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026 Table 11. Global Influenzavirus B Infection Drug Sales by Regions 2015-2020 (K Pcs) Table 12. Global Influenzavirus B Infection Drug Sales Market Share by Regions (2015-2020) Table 13. Global Influenzavirus B Infection Drug Revenue by Regions 2015-2020 (US$ Million) Table 14. Global Influenzavirus B Infection Drug Sales Forecast by Region (2021-2026) (K Pcs) Table 15. Global Influenzavirus B Infection Drug Sales by Manufacturers (2015-2020) (K Pcs) Table 16. Global Influenzavirus B Infection Drug Sales Share by Manufacturers (2015-2020) Table 17. Global Influenzavirus B Infection Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020) Table 18. Global Influenzavirus B Infection Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Influenzavirus B Infection Drug as of 2019) Table 19. Influenzavirus B Infection Drug Revenue by Manufacturers (2015-2020) (US$ Million) Table 20. Influenzavirus B Infection Drug Revenue Share by Manufacturers (2015-2020) Table 21. Key Manufacturers Influenzavirus B Infection Drug Price (2015-2020) (USD/Pcs) Table 22. Influenzavirus B Infection Drug Manufacturers Manufacturing Base Distribution and Headquarters Table 23. Manufacturers Influenzavirus B Infection Drug Product Type Table 24. Date of International Manufacturers Enter into Influenzavirus B Infection Drug Market Table 25. Manufacturers Mergers & Acquisitions, Expansion Plans Table 26. Global Influenzavirus B Infection Drug Sales by Type (2015-2020) (K Pcs) Table 27. Global Influenzavirus B Infection Drug Sales Share by Type (2015-2020) Table 28. Global Influenzavirus B Infection Drug Revenue by Type (2015-2020) (US$ Million) Table 29. Global Influenzavirus B Infection Drug Revenue Share by Type (2015-2020) Table 30. Influenzavirus B Infection Drug Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs) Table 31. Global Influenzavirus B Infection Drug Sales Share by Type (2021-2026) Table 32. Global Influenzavirus B Infection Drug Sales by Application (2015-2020) (K Pcs) Table 33. Global Influenzavirus B Infection Drug Sales Share by Application (2015-2020) Table 34. Global Influenzavirus B Infection Drug Sales Share by Application (2021-2026) Table 35. Global Influenzavirus B Infection Drug Sales Market Share Forecast by Application (2021-2026) Table 36. Global Influenzavirus B Infection Drug Revenue by Application (2015-2020) (US$ Million) Table 37. Global Influenzavirus B Infection Drug Revenue Market Share Forecast by Application (2021-2026) Table 38. Japan Influenzavirus B Infection Drug Sales (K Pcs) of Key Companies (2015-2020) Table 39. Japan Influenzavirus B Infection Drug Sales Share by Company (2015-2020) Table 40. Japan Influenzavirus B Infection Drug Revenue (US$ Million) by Company (2015-2020) Table 41. Japan Influenzavirus B Infection Drug Sales (K Pcs) by Type (2015-2020) Table 42. Japan Influenzavirus B Infection Drug Sales Share by Type (2015-2020) Table 43. Japan Influenzavirus B Infection Drug Revenue (US$ Million) Market Share by Type (2015-2020) Table 44. Japan Influenzavirus B Infection Drug Price (K Pcs) by Type (2015-2020) Table 45. Japan Influenzavirus B Infection Drug Sales (K Pcs) by Type (2021-2026) Table 46. Japan Influenzavirus B Infection Drug Sales Share by Type (2021-2026) Table 47. Japan Influenzavirus B Infection Drug Revenue (US$ Million) Market Share by Type (2021-2026) Table 48. Japan Influenzavirus B Infection Drug Revenue Share by Type (2021-2026) Table 49. Japan Influenzavirus B Infection Drug Price (K Pcs) by Type (2021-2026) Table 50. Japan Influenzavirus B Infection Drug Sales (K Pcs) by Application (2015-2020) Table 51. Japan Influenzavirus B Infection Drug Sales Share by Application (2015-2020) Table 52. Japan Influenzavirus B Infection Drug Revenue (US$ Million) Market Share by Application (2015-2020) Table 53. Japan Influenzavirus B Infection Drug Sales (K Pcs) by Application (2021-2026) Table 54. Japan Influenzavirus B Infection Drug Sales Share by Application (2021-2026) Table 55. Japan Influenzavirus B Infection Drug Revenue (US$ Million) Market Share by Application (2021-2026) Table 56. Japan Influenzavirus B Infection Drug Revenue Share by Application (2021-2026) Table 57. North America Influenzavirus B Infection Drug Sales by Country (2015-2020) (K Pcs) Table 58. North America Influenzavirus B Infection Drug Sales Market Share by Country (2015-2020) Table 59. North America Influenzavirus B Infection Drug Revenue by Country (2015-2020) (US$ Million) Table 60. North America Influenzavirus B Infection Drug Revenue Market Share by Country (2015-2020) Table 61. Europe Influenzavirus B Infection Drug Sales by Country (2015-2020) (K Pcs) Table 62. Europe Influenzavirus B Infection Drug Sales Market Share by Country (2015-2020) Table 63. Europe Influenzavirus B Infection Drug Revenue by Country (2015-2020) (US$ Million) Table 64. Europe Influenzavirus B Infection Drug Revenue Market Share by Country (2015-2020) Table 65. Asia Pacific Influenzavirus B Infection Drug Sales by Region (2015-2020) (K Pcs) Table 66. Asia Pacific Influenzavirus B Infection Drug Sales Market Share by Region (2015-2020) Table 67. Asia Pacific Influenzavirus B Infection Drug Revenue by Region (2015-2020) (US$ Million) Table 68. Asia Pacific Influenzavirus B Infection Drug Revenue Market Share by Region (2015-2020) Table 69. Latin America Influenzavirus B Infection Drug Sales by Country (2015-2020) (K Pcs) Table 70. Latin America Influenzavirus B Infection Drug Sales Market Share by Country (2015-2020) Table 71. Latin Americaa Influenzavirus B Infection Drug Revenue by Country (2015-2020) (US$ Million) Table 72. Latin America Influenzavirus B Infection Drug Revenue Market Share by Country (2015-2020) Table 73. Middle East and Africa Influenzavirus B Infection Drug Sales by Country (2015-2020) (K Pcs) Table 74. Middle East and Africa Influenzavirus B Infection Drug Sales Market Share by Country (2015-2020) Table 75. Middle East and Africa Influenzavirus B Infection Drug Revenue by Country (2015-2020) (US$ Million) Table 76. Middle East and Africa Influenzavirus B Infection Drug Revenue Market Share by Country (2015-2020) Table 77. AbbVie Inc Corporation Information Table 78. AbbVie Inc Description and Business Overview Table 79. AbbVie Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020) Table 80. AbbVie Inc Influenzavirus B Infection Drug Product Table 81. AbbVie Inc Recent Development Table 82. Adimmune Corp Corporation Information Table 83. Adimmune Corp Description and Business Overview Table 84. Adimmune Corp Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020) Table 85. Adimmune Corp Product Table 86. Adimmune Corp Recent Development Table 87. Altravax Inc Corporation Information Table 88. Altravax Inc Description and Business Overview Table 89. Altravax Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020) Table 90. Altravax Inc Product Table 91. Altravax Inc Recent Development Table 92. Amarillo Biosciences Inc Corporation Information Table 93. Amarillo Biosciences Inc Description and Business Overview Table 94. Amarillo Biosciences Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020) Table 95. Amarillo Biosciences Inc Product Table 96. Amarillo Biosciences Inc Recent Development Table 97. Aphios Corp Corporation Information Table 98. Aphios Corp Description and Business Overview Table 99. Aphios Corp Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020) Table 100. Aphios Corp Product Table 101. Aphios Corp Recent Development Table 102. BioCryst Pharmaceuticals Inc Corporation Information Table 103. BioCryst Pharmaceuticals Inc Description and Business Overview Table 104. BioCryst Pharmaceuticals Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020) Table 105. BioCryst Pharmaceuticals Inc Product Table 106. BioCryst Pharmaceuticals Inc Recent Development Table 107. Cadila Healthcare Ltd Corporation Information Table 108. Cadila Healthcare Ltd Description and Business Overview Table 109. Cadila Healthcare Ltd Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020) Table 110. Cadila Healthcare Ltd Product Table 111. Cadila Healthcare Ltd Recent Development Table 112. ContraFect Corp Corporation Information Table 113. ContraFect Corp Description and Business Overview Table 114. ContraFect Corp Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020) Table 115. ContraFect Corp Product Table 116. ContraFect Corp Recent Development Table 117. Daiichi Sankyo Company Ltd Corporation Information Table 118. Daiichi Sankyo Company Ltd Description and Business Overview Table 119. Daiichi Sankyo Company Ltd Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020) Table 120. Daiichi Sankyo Company Ltd Product Table 121. Daiichi Sankyo Company Ltd Recent Development Table 122. Fujifilm Holdings Corporation Corporation Information Table 123. Fujifilm Holdings Corporation Description and Business Overview Table 124. Fujifilm Holdings Corporation Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020) Table 125. Fujifilm Holdings Corporation Product Table 126. Fujifilm Holdings Corporation Recent Development Table 127. GlaxoSmithKline Plc Corporation Information Table 128. GlaxoSmithKline Plc Description and Business Overview Table 129. GlaxoSmithKline Plc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020) Table 130. GlaxoSmithKline Plc Product Table 131. GlaxoSmithKline Plc Recent Development Table 132. Green Cross Corp Corporation Information Table 133. Green Cross Corp Description and Business Overview Table 134. Green Cross Corp Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020) Table 135. Green Cross Corp Product Table 136. Green Cross Corp Recent Development Table 137. Inovio Pharmaceuticals Inc Corporation Information Table 138. Inovio Pharmaceuticals Inc Description and Business Overview Table 139. Inovio Pharmaceuticals Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020) Table 140. Inovio Pharmaceuticals Inc Product Table 141. Inovio Pharmaceuticals Inc Recent Development Table 142. Kineta Inc Corporation Information Table 143. Kineta Inc Description and Business Overview Table 144. Kineta Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020) Table 145. Kineta Inc Product Table 146. Kineta Inc Recent Development Table 147. Medicago Inc Corporation Information Table 148. Medicago Inc Description and Business Overview Table 149. Medicago Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020) Table 150. Medicago Inc Product Table 151. Medicago Inc Recent Development Table 152. MedImmune LLC Corporation Information Table 153. MedImmune LLC Description and Business Overview Table 154. MedImmune LLC Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020) Table 155. MedImmune LLC Product Table 156. MedImmune LLC Recent Development Table 157. Mucosis BV Corporation Information Table 158. Mucosis BV Description and Business Overview Table 159. Mucosis BV Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020) Table 160. Mucosis BV Product Table 161. Mucosis BV Recent Development Table 162. Novavax Inc Corporation Information Table 163. Novavax Inc Description and Business Overview Table 164. Novavax Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020) Table 165. Novavax Inc Product Table 166. Novavax Inc Recent Development Table 167. Park Active Molecules Corporation Information Table 168. Park Active Molecules Description and Business Overview Table 169. Park Active Molecules Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020) Table 170. Park Active Molecules Product Table 171. Park Active Molecules Recent Development Table 172. Romark Laboratories LC Corporation Information Table 173. Romark Laboratories LC Description and Business Overview Table 174. Romark Laboratories LC Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020) Table 175. Romark Laboratories LC Product Table 176. Romark Laboratories LC Recent Development Table 177. Sanofi Corporation Information Table 178. Sanofi Description and Business Overview Table 179. Sanofi Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020) Table 180. Sanofi Product Table 181. Sanofi Recent Development Table 182. Sanofi Pasteur SA Corporation Information Table 183. Sanofi Pasteur SA Description and Business Overview Table 184. Sanofi Pasteur SA Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020) Table 185. Sanofi Pasteur SA Product Table 186. Sanofi Pasteur SA Recent Development Table 187. Shionogi & Co Ltd Corporation Information Table 188. Shionogi & Co Ltd Description and Business Overview Table 189. Shionogi & Co Ltd Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020) Table 190. Shionogi & Co Ltd Product Table 191. Shionogi & Co Ltd Recent Development Table 192. SK Chemicals Co Ltd Corporation Information Table 193. SK Chemicals Co Ltd Description and Business Overview Table 194. SK Chemicals Co Ltd Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020) Table 195. SK Chemicals Co Ltd Product Table 196. SK Chemicals Co Ltd Recent Development Table 197. TSRL Inc Corporation Information Table 198. TSRL Inc Description and Business Overview Table 199. TSRL Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020) Table 200. TSRL Inc Product Table 201. TSRL Inc Recent Development Table 202. Vaxart Inc Corporation Information Table 203. Vaxart Inc Description and Business Overview Table 204. Vaxart Inc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020) Table 205. Vaxart Inc Product Table 206. Vaxart Inc Recent Development Table 207. Vectura Group Plc Corporation Information Table 208. Vectura Group Plc Description and Business Overview Table 209. Vectura Group Plc Influenzavirus B Infection Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020) Table 210. Vectura Group Plc Product Table 211. Vectura Group Plc Recent Development Table 212. Key Opportunities and Drivers: Impact Analysis (2021-2026) Table 213. Key Challenges Table 214. Market Risks Table 215. Main Points Interviewed from Key Influenzavirus B Infection Drug Players Table 216. Influenzavirus B Infection Drug Customers List Table 217. Influenzavirus B Infection Drug Distributors List Table 218. Research Programs/Design for This Report Table 219. Key Data Information from Secondary Sources Table 220. Key Data Information from Primary Sources List of Figures Figure 1. Influenzavirus B Infection Drug Product Picture Figure 2. Global Influenzavirus B Infection Drug Sales Market Share by Type in 2020 & 2026 Figure 3. APP-309 Product Picture Figure 4. CF-403 Product Picture Figure 5. GC-3106A Product Picture Figure 6. KIN-1400 Product Picture Figure 7. Others Product Picture Figure 8. Global Influenzavirus B Infection Drug Sales Market Share by Application in 2020 & 2026 Figure 9. Clinic Figure 10. Hospital Figure 11. Others Figure 12. Influenzavirus B Infection Drug Report Years Considered Figure 13. Global Influenzavirus B Infection Drug Market Size 2015-2026 (US$ Million) Figure 14. Global Influenzavirus B Infection Drug Sales 2015-2026 (K Pcs) Figure 15. Global Influenzavirus B Infection Drug Market Size Market Share by Region: 2020 Versus 2026 Figure 16. Global Influenzavirus B Infection Drug Sales Market Share by Region (2015-2020) Figure 17. Global Influenzavirus B Infection Drug Sales Market Share by Region in 2019 Figure 18. Global Influenzavirus B Infection Drug Revenue Market Share by Region (2015-2020) Figure 19. Global Influenzavirus B Infection Drug Revenue Market Share by Region in 2019 Figure 20. Global Influenzavirus B Infection Drug Sales Share by Manufacturer in 2019 Figure 21. The Top 10 and 5 Players Market Share by Influenzavirus B Infection Drug Revenue in 2019 Figure 22. Influenzavirus B Infection Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019 Figure 23. Global Influenzavirus B Infection Drug Sales Market Share by Type (2015-2020) Figure 24. Global Influenzavirus B Infection Drug Sales Market Share by Type in 2019 Figure 25. Global Influenzavirus B Infection Drug Revenue Market Share by Type (2015-2020) Figure 26. Global Influenzavirus B Infection Drug Revenue Market Share by Type in 2019 Figure 27. Global Influenzavirus B Infection Drug Market Share by Price Range (2015-2020) Figure 28. Global Influenzavirus B Infection Drug Sales Market Share by Application (2015-2020) Figure 29. Global Influenzavirus B Infection Drug Sales Market Share by Application in 2019 Figure 30. Global Influenzavirus B Infection Drug Revenue Market Share by Application (2015-2020) Figure 31. Global Influenzavirus B Infection Drug Revenue Market Share by Application in 2019 Figure 32. Japan Influenzavirus B Infection Drug Sales Growth Rate 2015-2026 (K Pcs) Figure 33. Japan Influenzavirus B Infection Drug Revenue Growth Rate 2015-2026 (US$ Million) Figure 34. Japan Influenzavirus B Infection Drug Market Share in Global Market 2015-2026 Figure 35. Japan 5 and 10 Largest Influenzavirus B Infection Drug Players Market Share by Revenue in Influenzavirus B Infection Drug in 2019 Figure 36. Japan Influenzavirus B Infection Drug Revenue Share by Type (2015-2020) Figure 37. Japan Influenzavirus B Infection Drug Revenue Growth Rate by Type in 2015 & 2019 Figure 38. Japan Influenzavirus B Infection Drug Revenue Share by Application (2015-2020) Figure 39. Japan Influenzavirus B Infection Drug Revenue Growth Rate by Application in 2015 & 2019 Figure 40. North America Influenzavirus B Infection Drug Sales Growth Rate 2015-2020 (K Pcs) Figure 41. North America Influenzavirus B Infection Drug Revenue Growth Rate 2015-2020 (US$ Million) Figure 42. North America Influenzavirus B Infection Drug Sales Market Share by Country in 2019 Figure 43. North America Influenzavirus B Infection Drug Revenue Market Share by Country in 2019 Figure 44. U.S. Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs) Figure 45. U.S. Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 46. Canada Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs) Figure 47. Canada Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 48. Europe Influenzavirus B Infection Drug Sales Growth Rate 2015-2020 (K Pcs) Figure 49. Europe Influenzavirus B Infection Drug Revenue Growth Rate 2015-2020 (US$ Million) Figure 50. Europe Influenzavirus B Infection Drug Sales Market Share by Country in 2019 Figure 51. Europe Influenzavirus B Infection Drug Revenue Market Share by Country in 2019 Figure 52. Germany Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs) Figure 53. Germany Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 54. France Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs) Figure 55. France Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 56. U.K. Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs) Figure 57. U.K. Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 58. Italy Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs) Figure 59. Italy Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 60. Russia Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs) Figure 61. Russia Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 62. Asia Pacific Influenzavirus B Infection Drug Sales Growth Rate 2015-2020 (K Pcs) Figure 63. Asia Pacific Influenzavirus B Infection Drug Revenue Growth Rate 2015-2020 (US$ Million) Figure 64. Asia Pacific Influenzavirus B Infection Drug Sales Market Share by Region in 2019 Figure 65. Asia Pacific Influenzavirus B Infection Drug Revenue Market Share by Region in 2019 Figure 66. China Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs) Figure 67. China Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 68. Japan Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs) Figure 69. Japan Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 70. South Korea Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs) Figure 71. South Korea Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 72. India Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs) Figure 73. India Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 74. Australia Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs) Figure 75. Australia Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 76. Taiwan Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs) Figure 77. Taiwan Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 78. Indonesia Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs) Figure 79. Indonesia Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 80. Thailand Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs) Figure 81. Thailand Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 82. Malaysia Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs) Figure 83. Malaysia Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 84. Philippines Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs) Figure 85. Philippines Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 86. Vietnam Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs) Figure 87. Vietnam Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 88. Latin America Influenzavirus B Infection Drug Sales Growth Rate 2015-2020 (K Pcs) Figure 89. Latin America Influenzavirus B Infection Drug Revenue Growth Rate 2015-2020 (US$ Million) Figure 90. Latin America Influenzavirus B Infection Drug Sales Market Share by Country in 2019 Figure 91. Latin America Influenzavirus B Infection Drug Revenue Market Share by Country in 2019 Figure 92. Mexico Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs) Figure 93. Mexico Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 94. Brazil Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs) Figure 95. Brazil Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 96. Argentina Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs) Figure 97. Argentina Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 98. Middle East and Africa Influenzavirus B Infection Drug Sales Growth Rate 2015-2020 (K Pcs) Figure 99. Middle East and Africa Influenzavirus B Infection Drug Revenue Growth Rate 2015-2020 (US$ Million) Figure 100. Middle East and Africa Influenzavirus B Infection Drug Sales Market Share by Country in 2019 Figure 101. Middle East and Africa Influenzavirus B Infection Drug Revenue Market Share by Country in 2019 Figure 102. Turkey Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs) Figure 103. Turkey Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 104. Saudi Arabia Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs) Figure 105. Saudi Arabia Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 106. U.A.E Influenzavirus B Infection Drug Sales Growth Rate (2015-2020) (K Pcs) Figure 107. U.A.E Influenzavirus B Infection Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 108. Porter's Five Forces Analysis Figure 109. Influenzavirus B Infection Drug Value Chain Figure 110. Channels of Distribution Figure 111. Distributors Profiles Figure 112. Bottom-up and Top-down Approaches for This Report Figure 113. Data Triangulation Figure 114. Key Executives Interviewed

AbbVie Inc Adimmune Corp Altravax Inc Amarillo Biosciences Inc Aphios Corp BioCryst Pharmaceuticals Inc Cadila Healthcare Ltd ContraFect Corp Daiichi Sankyo Company Ltd Fujifilm Holdings Corporation GlaxoSmithKline Plc Green Cross Corp Inovio Pharmaceuticals Inc Kineta Inc Medicago Inc MedImmune LLC Mucosis BV Novavax Inc Park Active Molecules Romark Laboratories LC Sanofi Sanofi Pasteur SA Shionogi & Co Ltd SK Chemicals Co Ltd TSRL Inc Vaxart Inc Vectura Group Plc